Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jun;45(4):1025-1035.
doi: 10.1111/opo.13517. Epub 2025 Apr 29.

Clinical evaluation of MyoCare in Europe (CEME) for myopia management: One-year results

Collaborators, Affiliations
Randomized Controlled Trial

Clinical evaluation of MyoCare in Europe (CEME) for myopia management: One-year results

Cristina Alvarez-Peregrina et al. Ophthalmic Physiol Opt. 2025 Jun.

Abstract

Aims: To evaluate the efficacy of CARE spectacle lenses in slowing myopia progression among European children.

Methods: In a 2-year randomised, parallel-group, double-masked, multicentre clinical trial, 234 European children aged 6-13 years were enrolled. All participants were myopic, with a cycloplegic spherical equivalent refractive error (SE) between -0.75 D and -5.00 D, astigmatism ≤1.50 D, anisometropia ≤1.00 D and myopia progression of at least 0.50 D in the previous year. The treatment group received MyoCare spectacle lenses with cylinder annular refractive elements (CARE), the control group single-vision lenses (SVL). Axial length (AL) and SE were measured at baseline, 6 and 12 months. Wearability questionnaires were administered at 1 week and 3 months. Central and peripheral visual acuity (VA) was recorded at dispensing and after 3 months. Generalised linear models estimated changes in SE and AL, adjusting for lens type, age and baseline measurements.

Results: After 12 months, children wearing CARE lenses showed less myopia progression, with a difference in SE and AL progression (compared to SVL) of -0.21 D (CI: 0.10 to 0.32 D) and 0.14 mm (CI: -0.17 to -0.10 mm), respectively. Central VA did not decrease with CARE lenses. Peripheral VA decreased by 0.10 and 0.09 logMAR in the nasal and temporal zones, respectively. Analysis of fast progressors indicated that 39.7% of SVL wearing eyes progressed by ≤-0.50 D/year compared to 21.1% with CARE (p < 0.01). For AL, 56.0% of SVL children had an elongation ≥0.20 mm compared to 21.3% with CARE (p < 0.01).

Conclusions: In European children, myopia progression was significantly slower with CARE lenses compared with SVL after 1 year of lens wear. Further monitoring will provide a comprehensive evaluation of long-term efficacy.

Keywords: Europe; children; myopia control; ophthalmic lens.

PubMed Disclaimer

Conflict of interest statement

Padmaja Sankaridurg is an employee of Carl Zeiss Vision International GmbH and is an inventor on patents and patent applications assigned to Brien Holden Vision Institute and ZEISS Vision Care; Nicole Liu is an employee of Carl Zeiss Vision International GmbH; Arne Ohlendorf is an employee of Carl Zeiss Vision International GmbH; Wayne Li is an employee of ZEISS Vision Care Guangzhou; Cristina Alvarez is a member of the Zeiss Myopia Advisory Board. No conflicts of interest exist for the remaining authors.

Figures

FIGURE 1
FIGURE 1
Schematic illustration of the features in the cylindrical annular refractive elements (CARE) spectacle lens.
FIGURE 2
FIGURE 2
Study Flowchart. CARE, cylindrical annular refractive elements spectacle lens; SVL, single vision lens; t, time.
FIGURE 3
FIGURE 3
(a) Spherical equivalent refractive error progression over time; (b) Axial length progression over time. Study lens: Cylindrical annular refractive elements spectacle lens (MyoCare); Control, single vision lens (SVL).

Similar articles

References

    1. Holden B, Wilson D, Jong M, Sankaridurg P, Fricke TR, Smith EL III, et al. Myopia: a growing global problem with sight‐threatening complications. Community Eye Health. 2015;28:35. Accessed January 15, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC4675264/pdf/jceh_28_90_035.pdf - PMC - PubMed
    1. Shah R, Vlasak N, Evans BJW. High myopia: reviews of myopia control strategies and myopia complications. Ophthalmic Physiol Opt. 2024;44:1248–1260. - PubMed
    1. Lawrenson J, Shah R, Huntjens B, Lawrenson JG, Downie LE, Virgili G, et al. Interventions for myopia control in children: a living systematic review and network meta‐analysis. Cochrane Database Syst Rev. 2023;2:CD014758. 10.1002/14651858.cd014758.pub2 - DOI - PMC - PubMed
    1. Lam CSY, Tang WC, Zhang HY, Lee PH, Tse DYY, Qi H, et al. Long‐term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. Sci Rep. 2023;13:5475. 10.1038/s41598-023-32700-7 - DOI - PMC - PubMed
    1. Li X, Huang Y, Yin Z, Liu C, Zhang S, Yang A, et al. Myopia control efficacy of spectacle lenses with aspherical Lenslets: results of a 3‐year follow‐up study. Am J Ophthalmol. 2023;253:160–168. - PubMed

Publication types

Grants and funding